Mirum Pharmaceuticals Inc (MIRM) USD0.0001

Sell:$44.13Buy:$57.30$1.48 (3.05%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$44.13
Buy:$57.30
Change:$1.48 (3.05%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$44.13
Buy:$57.30
Change:$1.48 (3.05%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Key people

Peter Radovich
President, Chief Operating Officer
Christopher Peetz
Chief Executive Officer, Co-Founder, Director
Eric H. Bjerkholt
Chief Financial Officer
Pamela Vig
Chief Scientific Officer
Lara Longpre
Chief Development Officer
Joanne Quan
Chief Medical Officer
Michael G. Grey
Independent Non-Executive Chairman of the Board
Laura A. Brege
Independent Director
Lon Cardon
Independent Director
William Carl Fairey
Independent Director
Laurent Fischer
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6047491013
  • Market cap
    $2.33bn
  • Employees
    311
  • Shares in issue
    48.00m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.